{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000037","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.453530+00:00","generated_at":"2026-05-25T23:37:56.648997+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Praxis Essential3 interim analysis recommends futility; studies continue to Q3 2025","bullets":["IDMC recommended stopping Essential3 Study 1 for futility; Praxis continues both studies to completion.","Topline results for Essential3 now expected Q3 2025; NDA decision after final data.","Cash, equivalents and marketable securities of $469.5M as of Dec 31, 2024, up from $81.3M.","Net loss for Q4 2024 was $58.7M vs. $26.9M in Q4 2023; R&D spend rose to $56.3M from $18.4M.","UCB exercised option to in-license KCNT1 candidate; Praxis eligible for up to ~$100M in milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000037","json":"https://secwatch.observer/filing/0001689548-25-000037.json","markdown":"https://secwatch.observer/filing/0001689548-25-000037.md","text":"https://secwatch.observer/filing/0001689548-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/0001689548-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/prax-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:37:56.648997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}